Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis
Annals of Hematology · 20.11.2026
DOI: 10.1007/s00277-026-07370-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Hematology, online erschienen am 20.11.2026. Verfasst von Saira Khan und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Khan, S., Khaliq, S., Hanzala, M., Khan, Z., Masood, S., Abedin, Z. U., Abideen, Z. U., Khair, A. N., Fatima, N., Shahid, I. F., Tahir, M. Z., Khalid, H. B., & Amin, M. H. J. (2026). Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07370-w
Vancouver
Khan S, Khaliq S, Hanzala M, Khan Z, Masood S, Abedin ZU, et al. Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Annals of Hematology. 2026. doi:10.1007/s00277-026-07370-w
BibTeX
@article{Khan2026,
author = {Khan, Saira and Khaliq, Shahzaib and Hanzala, Muhammad and Khan, Zoha and Masood, Saad and Abedin, Zain Ul and Abideen, Zain ul and Khair, Ayefa Naveed and Fatima, Nayab and Shahid, Ishmal Fatima and Tahir, Muhammad Zubair and Khalid, Haider Bin and Amin, Mohammad Hammad Jaber},
title = {Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07370-w}
}
EUVIMED